Objectives: To evaluate the outcomes associated with extubation during extracorporeal membrane oxygenation (ECMO) in pediatric patients.
Design: Retrospective cohort study using the Extracorporeal Life Support Organization (ELSO) registry, 2018-2022.
Setting: Multicenter and international database of all ECMO centers in the ELSO registry.
Patients: Patients between 30 days and 18 years old receiving pulmonary ECMO support.
Interventions: None.
Measurements And Main Results: Overall, 2178 patients were included, of which 105 were extubated during ECMO support (4.8%). Analysis of pre-ECMO data failed to identify an association between extubation strategy and severity using the Pediatric Pulmonary Rescue with ECMO Prediction (P-PREP) score. Use of extubation, vs. not, was associated with older age (median, 6.1 vs. 2.5 yr; p = 0.006), and longer ECMO duration (median 12.9 vs. 7.1 d; p < 0.0001). We failed to identify an association between the use of extubation, vs. not, and ECMO complications. In a propensity matching analysis with 3:1 matching of nonextubated to extubated cases, mortality was 34.3% and 43.8%, respectively (p = 0.08). In the matched subset, extubation, vs. not, was associated with shorter median PICU length of stay (LOS) after decannulation (6.6 vs. 12.2 d; p = 0.001) and higher use of mobilization (28.6% vs. 9.8%; p < 0.0001). In a multivariable analysis, we failed to identify an association between using the extubation strategy, vs. not, and greater odds of mortality (odds ratio, 1.74; 95% CI, 0.94-3.27; p = 0.08). However, we cannot exclude the possibility that the use of an extubation strategy is associated with greater odds of mortality.
Conclusions: In the 2018-2022 ELSO registry data, extubating pediatric patients on ECMO for pulmonary cause was an uncommon practice, associated with improved mobility and decreased ICU LOS after ECMO decannulation. However, given the concerns about mortality, careful consideration of patient candidacy and further studies are needed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PCC.0000000000003711 | DOI Listing |
Am J Obstet Gynecol
March 2025
Social, Statistical, & Environmental Sciences, RTI International, Research Triangle Park, NC, United States.
Background: Prior studies have failed to demonstrate clinical or statistical difference in fecal incontinence (FI) symptom improvement with neuromodulation by percutaneous tibial nerve stimulation (PTNS) vs sham. The results of these studies may be indicative of a placebo or sham effect and led us to investigate possible genetic biomarkers of placebo response among women with FI.
Objective: To evaluate the relationship between response to PTNS or sham and genetic polymorphisms associated with placebo response in women with FI.
Arch Pathol Lab Med
March 2025
From Translational Medicine, ImmunoGen, Inc, Waltham, Massachusetts (Deutschman, Sloss).
Context.—: The VENTANA FOLR1 (FOLR1-2.1) RxDx (FOLR1 CDx) assay, developed by Roche Tissue Diagnostics, is a Food and Drug Administration-approved immunohistochemical assay intended for use in the assessment of folate receptor α (FRα) expression in formalin-fixed, paraffin-embedded epithelial ovarian, fallopian tube, and primary peritoneal tumor specimens.
View Article and Find Full Text PDFChild Abuse Negl
March 2025
Department of Forensic Medicine, Monash University, Melbourne, Australia. Electronic address:
Background: Paediatricians serve as expert witnesses in child maltreatment cases, informing decision-makers about injury mechanisms, likely injury-dates, and consequences. Despite paediatricians' multifaceted role in responding to child maltreatment, the impacts on paediatricians of their involvement in legal processes are not well understood.
Objective: This systematic scoping review identified and synthesized scientific research findings on the benefits and harms to doctors, particularly paediatricians, who testify in child maltreatment cases.
Pediatr Infect Dis J
March 2025
From the Department of Pediatrics.
Background: Critically ill children are at risk for subtherapeutic antibiotic concentrations. The frequency of target attainment and risk factors for subtherapeutic concentrations of cefepime in children have not been extensively studied.
Methods: We performed an observational study in critically ill children receiving a new prescription of standard dosing of cefepime for suspected sepsis (≥2 systemic inflammatory response syndrome criteria within 48 hours of cefepime start).
Pain Med
March 2025
Department of Anesthesiology and Pain Medicine, Université de Montréal, 2900 Boul. Edouard-Montpetit, Montréal, Québec, H3T 1J4, Canada.
Design: Platelet-rich plasma (PRP) is a popular treatment option in managing chronic tendinopathies, although the literature is inconsistent, mainly because of significant heterogeneity in patient populations. Patients who failed conservative management may respond differently than those who have not undergone first-line treatment. This systematic review and meta-analysis aimed to evaluate the efficacy of PRP injections in reducing pain and improving function in patients with chronic tendinopathy who failed conservative treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!